Marsh & McLennan GC sells 1,197 shares after exercise

The SVP and General Counsel of MARSH & MCLENNAN COMPANIES, INC. exercised and sold 1,197 shares in an options-related transaction without a reported Rule 10b5-1 plan.

Rhea-AI Filing Summary

MARSH & MCLENNAN COMPANIES, INC. (MRSH) reported that Katherine Brennan, its Senior Vice President and General Counsel, exercised employee stock options covering 1,197 shares of common stock on September 2, 2026 at an exercise price of $83.046 per share, then sold 1,197 shares of common stock at $187.899 per share the same day. The underlying options, granted on February 21, 2018 and vesting annually from 2019 through 2022, are now fully exercised with no shares remaining from that grant, and no Rule 10b5-1 trading plan is reported for these transactions.

Insider Trade Summary

Exercise and Sale: 1,197 shares ($126K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Brennan Katherine

Role SVP and General Counsel

Sold 1,197 shs ($225K)

Approx. gross sale proceeds $225K

Approx. exercise cost $99K

Approx. pre-tax spread $126K

Type	Security	Shares	Price	Value
Exercise	Stock Options (Right to Buy) F1	1,197	$0.00	$0.00
Exercise	Common Stock	1,197	$83.046	$99K
Sale	Common Stock	1,197	$187.899	$225K

Holdings After Transaction: Stock Options (Right to Buy) — 0 contracts (Direct); Common Stock — 7,330 shares (Direct)

Footnotes (1)

1. F1. These options were granted on February 21, 2018 and vested in four equal annual installments on February 21st of 2019, 2020, 2021 and 2022.

Key Figures

Options exercised: 1,197 shares Option exercise price: $83.046 per share Shares sold: 1,197 shares +5 more

8 metrics

Options exercised 1,197 shares Stock options for common stock exercised by Katherine Brennan on September 2, 2026

Option exercise price $83.046 per share Exercise price for 1,197 options exercised on September 2, 2026

Shares sold 1,197 shares Common stock sold by Katherine Brennan on September 2, 2026

Sale price $187.899 per share Price for 1,197 common shares sold on September 2, 2026

Options remaining from this grant 0 options Total stock options from the February 21, 2018 grant following the reported exercise

Option grant date February 21, 2018 Original grant date of the stock options exercised on September 2, 2026

Option expiration date February 20, 2028 Expiration date of the stock options that were exercised

Vesting schedule Four equal annual installments in 2019, 2020, 2021, 2022 Vesting pattern for the February 21, 2018 option grant

Key Terms

Stock Options (Right to Buy), Exercise or conversion of derivative security, Sale in open market or private transaction

3 terms

Stock Options (Right to Buy) financial

"Stock Options (Right to Buy) granted on February 21, 2018"

Exercise or conversion of derivative security financial

"Reported as an exercise or conversion of derivative security"

Sale in open market or private transaction financial

"Classified as a sale in open market or private transaction"

FAQ

What insider transaction did MARSH & MCLENNAN COMPANIES, INC. (MRSH) report for Katherine Brennan?

Katherine Brennan, Senior Vice President and General Counsel, exercised options for 1,197 shares of common stock at $83.046 per share and sold 1,197 shares at $187.899 per share on September 2, 2026, fully using that option grant.

How many MRSH shares did Katherine Brennan sell and at what price?

Katherine Brennan sold 1,197 shares of MARSH & MCLENNAN COMPANIES, INC. common stock at a price of $187.899 per share on September 2, 2026, in a reported sale following an option exercise.

What was the exercise price of the options used in the MRSH Form 4 transaction?

The options exercised by Katherine Brennan on September 2, 2026 had an exercise price of $83.046 per share and related to 1,197 shares of MARSH & MCLENNAN COMPANIES, INC. common stock.

When were the options in the MRSH Form 4 originally granted and how did they vest?

The options were granted on February 21, 2018 and vested in four equal annual installments on February 21 of 2019, 2020, 2021 and 2022, as described in the footnote to the filing.

Were the reported MRSH transactions under a Rule 10b5-1 trading plan?

No. The Form 4 indicates that no Rule 10b5-1 trading plan is reported for the transactions disclosed for Katherine Brennan on September 2, 2026.

Do any options from this specific MRSH grant remain after the transaction?

No. After exercising options covering 1,197 shares, the Form 4 reports that 0 options from this particular February 21, 2018 grant remain outstanding.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/03/2026 - 04:03 PM Accepted by SEC EDGAR 09/03/2026 - 04:02 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Brennan Katherine

(Last) (First) (Middle)

1166 AVENUE OF THE AMERICAS

(Street)

NEW YORK NEW YORK 10036

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MARSH & MCLENNAN COMPANIES, INC. [ MRSH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP and General Counsel

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/02/2026		M		1,197	A	$83.046	8,527	D
Common Stock	09/02/2026		S		1,197	D	$187.899	7,330	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (Right to Buy)	$83.046	09/02/2026		M			1,197	(1)	02/20/2028	Common Stock	1,197	$0	0	D

Explanation of Responses:

1. These options were granted on February 21, 2018 and vested in four equal annual installments on February 21st of 2019, 2020, 2021 and 2022.

	/s/ Tessa Patti, Attorney-in-fact	09/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)